AARD — Aardvark Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary
Brief: Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol
U.S. STOCKS ON THE MOVE-Invivyd, US natgas companies, New Era Energy
U.S. STOCKS ON THE MOVE-Invivyd, US natgas companies, New Era Energy
Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise
Brief: Aardvark Therapeutics Announces FDA Alignment On Protocol Amendment Expanding Phase 3 Hero Trial Population For Prader-Willi Syndrome
U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair
LB Pharmaceuticals raises $285 million in US IPO (updated)
Live Markets: Prader-Willi drug sparks Wall Street interest in multi-billion dollar market, Leerink says
Brief: Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss As A Monotherapy, Enhancement Of GLP-1RA Therapy In Combination, And Effective Maintenance Following Discontinuation Of GLP-1RA Therapy
Brief: Aardvark Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
Ultragenyx Pharma up after JPMorgan PT raise
Brief: Aardvark Therapeutics Prices IPO Of 5.9 Million Shares At $16.00 Per Share